Financings In Brief
This article was originally published in The Gray Sheet
Executive Summary
Insulet proposes $107 mil. IPO: Maker of the OmniPod insulin management system proposes initial public offering, comprising 6.7 million common stock shares at $14 to $16 each and valued at up to $107 million. Proceeds are tabbed for expansion of manufacturing capacity and marketing activities, plus R&D. About 1,750 U.S. patients with diabetes use OmniPod. Cleared via 510(k) in January 2005 and launched in the United States that October, OmniPod includes a small insulin infusion pump that adheres to the skin and can be worn under clothing, and a handheld, wireless programmer that incorporates a blood glucose meter (1"The Gray Sheet" June 6, 2005, p. 16). The Bedford, Mass., firm generated sales of $3.7 million in 2006 and has an accumulated deficit of $102 million. Underwriters include JP Morgan Securities, Merrill Lynch, Thomas Weisel Partners and Leerink Swann & Company...
You may also be interested in...
Financings In Brief
Pegasus Biologics closes $20 mil. private placement: The DurAdapt bioimplant for dura mater repair after craniotomies is among Pegasus Biologics' R&D projects to be bolstered by a $20 million private placement, announced May 10. The firm also is developing a graft for anterior cruciate ligament reconstruction. Current offerings include the 510(k)-cleared OrthAdapt bioimplant for reinforcing compromised soft tissues in sports medicine, orthopedic and spine applications. The device is a "biocompatible, stabilized, sterilized collagen scaffold that fortifies and promotes tissue ingrowth," the Irvine, Calif., firm explains. Pegasus also offers the Unite biomatrix wound dressing. The new funds, which bring the company's total private equity investment to nearly $32 milion, will help Pegasus expand its market reach while bolstering its development pipeline, the firm says. The "Series C" financing round was led by Onset Ventures...
Financings In Brief
Pegasus Biologics closes $20 mil. private placement: The DurAdapt bioimplant for dura mater repair after craniotomies is among Pegasus Biologics' R&D projects to be bolstered by a $20 million private placement, announced May 10. The firm also is developing a graft for anterior cruciate ligament reconstruction. Current offerings include the 510(k)-cleared OrthAdapt bioimplant for reinforcing compromised soft tissues in sports medicine, orthopedic and spine applications. The device is a "biocompatible, stabilized, sterilized collagen scaffold that fortifies and promotes tissue ingrowth," the Irvine, Calif., firm explains. Pegasus also offers the Unite biomatrix wound dressing. The new funds, which bring the company's total private equity investment to nearly $32 milion, will help Pegasus expand its market reach while bolstering its development pipeline, the firm says. The "Series C" financing round was led by Onset Ventures...
Financings In Brief
Accuray goes public: Maker of the CyberKnife robotic radiosurgery system tabs $50 million of its $171.3 million in initial public offering proceeds to expand marketing efforts for the device while another $40 million is for R&D, according to the company. Accuray's IPO Feb. 8 consisted of 18.4 million shares priced at $18 each - including 10.4 million shares offered by the company and 8 million shares offered by selling shareholders - totaling $331.2 million. CyberKnife is 510(k) cleared to provide treatment planning and image-guided robotic radiosurgery for tumors anywhere in the body where radiation treatment is indicated (1"The Gray Sheet" Dec. 1, 2003, p. 15). Accuray reported revenue of $52.9 million in fiscal 2006 (ended June 30) - a 136% leap from the prior year. The firm's net loss of $33.7 million in 2006 compares to a loss of $25.2 million a year earlier. Accuray competes primarily with makers of frame-based radiosurgery systems including Elekta, BrainLab and Integra Life Sciences. Other radiotherapy system makers include Siemens, Varian Medical, Elekta and TomoTherapy. Radiosurgery differs from traditional radiotherapy in that it delivers a high dose of radiation directly to a tumor rather than the surrounding area, Accuray explains. Underwriters for the IPO include JP Morgan, UBS Investment Bank, Piper Jaffray and Jefferies & Company...